Dr Fredrik Schjesvold speaks to ecancer at the 2019 ASH meeting in Orlando about the latest results rom the phase II CONPET trial which investigated the use of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET/CT) positivity as an indication for KRd (carfilzomib, lenalidomide and dexamethasone) consolidation therapy after first-line treatment with autologous stem cell transplantation (ASCT) in multiple myeloma (MM).
He explains the results achieved in this phase of the trial, in which 37 percent of patients who were treated with first-lien therapy displayed positive partial responses and were considered FDG PET/CT positive.
Dr Schjesvold mentions that the potential clinical benefits are unclear at this point, due to the small sample size. But, the PET negative patients appear to have a better prognosis - however longer follow-up is needed.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.